
LG Life Sciences, and all other Korean pharma companies for that matter, should be global players and should not be content with the current 1.5 percent share of the global pharmaceutical market
Tags:
Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach,…
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…
See our Cookie Privacy Policy Here